Axitinib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) of clear cell histology after failure of one prior systemic therapy with sunitinib, cytokine or sorafenib (see Pharmacology: Pharmacodynamics under Actions).
Axitinib should be prescribed by a qualified healthcare professional who is experienced in the use of anti-neoplastic therapy.